First-in-human phase 1 RCT of SOL-116, an anti-BSSL antibody, vs placebo in 48 healthy participants and 8 patients with rheumatoid arthritis: it was safe and well tolerated, lowered free BSSL, but gave no clear change in exploratory inflammation markers.
RCTn = 56
Meijs et al. First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients